We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
SARS‐CoV‐2 infection among patients with haematological disorders: Severity and one‐month outcome in 66 Danish patients in a nationwide cohort study.
- Authors
Glenthøj, Andreas; Jakobsen, Lasse H.; Sengeløv, Henrik; Ahmad, Syed A.; Qvist, Kristian; Rewes, Annika; Poulsen, Christian B.; Overgaard, Ulrik M.; Mølle, Ingolf; Severinsen, Marianne T.; Strandholdt, Casper N.; Maibom, Jack; Kodahl, Annette R.; Ryg, Jesper; Ravn, Pernille; Johansen, Isik S.; Helsø, Søren N.; Jensen‐Fangel, Søren; Kisielewicz, Jacek; Wiese, Lothar
- Abstract
Objectives: Patients with haematological disorders may be particularly vulnerable to respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection; however, this is unknown. Methods: We conducted a prospective, nationwide study including 66 patients in follow‐up at Danish haematology departments with a malignant or non‐malignant haematological disorder and with verified SARS‐CoV‐2 infection. Outcomes were intensive care unit (ICU) admission and one‐month survival rate. Results: Mean age was 66.7 years, 60.6% were males, 90.9% had comorbidity, and 13.6% had a BMI ≥ 30. The most frequent diagnoses were chronic lymphocytic leukaemia/lymphoma (47.0%), multiple myeloma (16.7%) and acute leukaemia/myelodysplastic syndrome (AL/MDS) (12.1%). Treatment for the haematological disease was ongoing in 59.1% of cases. Neutropenia was present in 6.5%, lymphopenia in 46.6% and hypogammaglobulinaemia in 26.3%. The SARS‐CoV‐2 infection was mild in 50.0%, severe in 36.4% and critical in 13.6%. After one month, 21.2% had been admitted to ICU, and 24.2% died. Mortality was highest in older patients, patients with severe/critical SARS‐CoV‐2 infection, high comorbidity score or high performance status score, purine analogue treatment and with AL/MDS. Although older patients and patients with comorbidities had the highest mortality rates, mortality was considerable among all haematological patients. Conclusion: Haematological patients with SARS‐CoV‐2 infection has a severe clinical course.
- Subjects
SARS-CoV-2; ACUTE leukemia; LYMPHOCYTIC leukemia; CHRONIC leukemia; OLDER patients; LYMPHOPENIA
- Publication
European Journal of Haematology, 2021, Vol 106, Issue 1, p72
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/ejh.13519